Ascendis Pharma ADR
(ASND)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 696,989 | 605,482 | 424,439 | 468,607 | 527,979 |
| Marketable Securities | N/A | N/A | 7,874 | 306,269 | 278,971 |
| Receivables | 178,417 | 192,008 | 60,363 | 27,000 | 27,431 |
| Inventories | 341,154 | 319,879 | 226,126 | 137,677 | 89,212 |
| TOTAL | $1,254,706 | $1,147,958 | $760,555 | $972,969 | $953,444 |
| Non-Current Assets | |||||
| PPE Net | 165,726 | 106,818 | 119,739 | 136,015 | 149,129 |
| Investments And Advances | 36,800 | 14,690 | 6,154 | 32,055 | 172,621 |
| Intangibles | 4,198 | 4,359 | 4,783 | 5,087 | 6,237 |
| Other Non-Current Assets | 12,298 | 2,507 | 2,302 | 2,023 | 2,139 |
| TOTAL | $219,022 | $128,374 | $132,978 | $175,179 | $330,126 |
| Total Assets | $1,473,728 | $1,276,332 | $893,533 | $1,148,148 | $1,283,570 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 550,462 | 531,891 | 12,150 | 26,784 | N/A |
| Accounts payable and accrued liabilities | 102,569 | 104,308 | 102,349 | 106,447 | 70,296 |
| Other current liabilities | 549,606 | 344,877 | 81,258 | 41,436 | 39,925 |
| TOTAL | $1,209,909 | $982,399 | $213,585 | $180,451 | $118,731 |
| Non-Current Liabilities | |||||
| Long Term Debt | 435,876 | 395,053 | 578,214 | 508,842 | N/A |
| Deferred Revenues | N/A | N/A | N/A | N/A | 8,276 |
| Other Non-Current Liabilities | 1,271 | 5,410 | 259,421 | 181,391 | 119,410 |
| TOTAL | $448,034 | $408,317 | $837,635 | $690,233 | $119,410 |
| Total Liabilities | $1,657,943 | $1,390,716 | $1,051,221 | $870,685 | $238,142 |
| Shareholders' Equity | |||||
| Common Shares | 9,416 | 8,818 | 8,387 | 8,086 | 9,046 |
| Retained earnings | -3,055,219 | -2,769,851 | -2,464,500 | -1,960,215 | -1,672,732 |
| Other shareholders' equity | -2,076 | 1,807 | 622 | 3,479 | 241,449 |
| TOTAL | $-184,216 | $-114,385 | $-157,688 | $277,463 | $1,045,429 |
| Total Liabilities And Equity | $1,473,727 | $1,276,332 | $893,533 | $1,148,148 | $1,283,571 |